确定关键基因,区分稳定和不稳定的动脉样板:生物信息和计算分析
Maryam Mahjoubin-Tehran1, Raul D Santos2, Wael Almahmeed3
1Applied Biomedical Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Current vascular pharmacology
|April 19, 2024
概括
这项研究确定了区分稳定和不稳定的动脉样硬化斑块的关键基因. 像PDE5A,PROS1,SOCS3,HBEGF和LILRB4这样的生物标志物可以预测斑块脆弱性.
科学领域:
- 心血管研究研究心血管研究
- 基因组学就是基因组学.
- 生物标志物发现发现
背景情况:
- 动脉样硬化斑块的脆弱性很难预测.
- 确定稳定与不稳定的斑块的生物标志物对于患者风险分层至关重要.
研究的目的:
- 确定与动脉样硬化斑块稳定性相关的关键基因.
- 发现潜在的生物标志物来预测斑块脆弱性.
主要方法:
- 使用的基因表达综合 (GEO) 数据集 (GSE71226, GSE20680, GSE62646, GSE34822).
- 在健康,稳定和不稳定的斑块样本之间比较差异表达的基因.
- 使用Cytoscape,STRING和GeneMANIA分析了基因网络.
主要成果:
- 在不同的比较组中选了10和12个关键基因.
- 确定了表皮生长因子 (EGF),肝素结合性EGF类似生长因子 (HBEGF) 和矩阵金属蛋白酶9 (MMP9) 作为核心网络基因.
- 验证了固酶5A (PDE5A) 和蛋白质S (PROS1) 的降低,而抑制细胞因子信号传递 (SOCS3),HBEGF和白细胞免疫球蛋白样受体B4 (LILRB4) 在不稳定的斑块中增加.
结论:
- 成功识别了与稳定和不稳定的动脉样硬化斑块相关的关键基因.
- 这些发现有助于理解斑块脆弱性和潜在的诊断标记.
相关概念视频
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:30Atherosclerosis I: Introduction
Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...